Evidence-based recommendations on endobronchial valve insertion to reduce lung volume in emphysema
Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis (excessive sweating) in adults
Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure
Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias (an inserted device to help the heart beat at a normal rate)
Evidence-based recommendations on platelet-rich plasma injections for knee osteoarthritis in adults (deterioration of the articular cartilage and menisci)
Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults
This guideline has been updated and replaced by NICE guideline NG101.
This guideline has been updated and replaced by NICE guideline NG128.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
In January 2020, we withdrew this guidance to allow for further consultation with stakeholders. See the guideline in development page for further information.